NO20010390L - Behandling av angstsykdommer - Google Patents

Behandling av angstsykdommer

Info

Publication number
NO20010390L
NO20010390L NO20010390A NO20010390A NO20010390L NO 20010390 L NO20010390 L NO 20010390L NO 20010390 A NO20010390 A NO 20010390A NO 20010390 A NO20010390 A NO 20010390A NO 20010390 L NO20010390 L NO 20010390L
Authority
NO
Norway
Prior art keywords
treatment
anxiety disorders
anatonist
serotonin
mammal
Prior art date
Application number
NO20010390A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010390D0 (no
Inventor
Lee Alan Phebus
Tammy Joy Sajdyk
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20010390D0 publication Critical patent/NO20010390D0/no
Publication of NO20010390L publication Critical patent/NO20010390L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20010390A 1998-07-27 2001-01-23 Behandling av angstsykdommer NO20010390L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9431098P 1998-07-27 1998-07-27
PCT/US1999/015475 WO2000006082A2 (fr) 1998-07-27 1999-07-08 Traitement des troubles anxieux

Publications (2)

Publication Number Publication Date
NO20010390D0 NO20010390D0 (no) 2001-01-23
NO20010390L true NO20010390L (no) 2001-03-13

Family

ID=22244420

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010390A NO20010390L (no) 1998-07-27 2001-01-23 Behandling av angstsykdommer

Country Status (14)

Country Link
EP (1) EP0976747A3 (fr)
JP (1) JP2003527305A (fr)
KR (1) KR20010072064A (fr)
CN (1) CN1315830A (fr)
AU (1) AU4977899A (fr)
BR (1) BR9913348A (fr)
CA (1) CA2338740A1 (fr)
EA (1) EA200100182A1 (fr)
HU (1) HUP0102886A3 (fr)
IL (1) IL140540A0 (fr)
NO (1) NO20010390L (fr)
PL (1) PL366197A1 (fr)
TR (1) TR200100240T2 (fr)
WO (1) WO2000006082A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2049601A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Benzofuran derivatives
ES2220582T3 (es) * 1999-12-20 2004-12-16 Eli Lilly And Company Derivados de piperidina y su uso como antagonistas de receptor de serotonina.
US7144898B2 (en) 1999-12-20 2006-12-05 Eli Lilly And Company Indole derivatives for the treatment of depression and anxiety
US20090043117A1 (en) * 2005-02-17 2009-02-12 Bayer Cropscience Aktiengesellschaft Process For Preparing (Disubstitutedpropenyl) Phenylalkyl Substituted Dihydrobenzofurans
BRPI0607720A2 (pt) * 2005-02-17 2009-10-06 Bayer Cropscience Ag processo aperfeiçoado para a preparação de diidrobenzofuranos substituìdos por (propenil dissubstituìdos) fenilalquila
JP2008534507A (ja) * 2005-03-23 2008-08-28 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 殺虫活性を有する（二置換プロペニル）フェニルアルキル置換ジヒドロベンゾフランを調製するための改善された方法
CN107973766B (zh) * 2016-10-21 2020-06-19 石家庄诚志永华显示材料有限公司 含有环烷基的氧芴衍生物的液晶化合物及其应用
TWI744458B (zh) * 2017-02-27 2021-11-01 日商捷恩智股份有限公司 具有二苯并呋喃環的化合物、液晶組成物及液晶顯示元件

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2941597A1 (de) * 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists

Also Published As

Publication number Publication date
KR20010072064A (ko) 2001-07-31
WO2000006082A3 (fr) 2000-05-04
EP0976747A3 (fr) 2000-09-13
HUP0102886A3 (en) 2002-12-28
EP0976747A2 (fr) 2000-02-02
WO2000006082A2 (fr) 2000-02-10
HUP0102886A2 (en) 2002-06-29
PL366197A1 (en) 2005-01-24
BR9913348A (pt) 2001-06-12
TR200100240T2 (tr) 2002-01-21
AU4977899A (en) 2000-02-21
EA200100182A1 (ru) 2001-08-27
CN1315830A (zh) 2001-10-03
CA2338740A1 (fr) 2000-02-10
IL140540A0 (en) 2002-02-10
NO20010390D0 (no) 2001-01-23
JP2003527305A (ja) 2003-09-16

Similar Documents

Publication Publication Date Title
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
NO20010844L (no) Regulering av substrataktivitet
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
NO20013155L (no) Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
RU98100755A (ru) Соединения нейроактивных стероидов из рядов андростана и прегнана, фармацевтический препарат, содержащий указанное соединение, способ модулирования комплекса рецептор гамка - хлоридный ионофор на животном объекте, способы лечения или профилактики стресса или состояния тревоги, судорожной активности, бессонницы, предменструального синдрома или послеродовой депрессии, нарушений настроения у животного объекта, способ индукции сна и поддержания значительно уровня rem-сна, способ индукции анестезии у животного объекта
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
DK1140181T3 (da) Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
NO20010390L (no) Behandling av angstsykdommer
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
SE9603725D0 (sv) New teatment
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
KR890701099A (ko) 기침 및 기관지 협착을 치료하기 위한 5-ht3 수용기 길항물질
DK556984A (da) Apparat til forebyggelse og behandling af svulster, caries og andre lidelser med vaesentlig reduktion af smerter ved hjaelp af elektriskeog/eller magnetiske impulser
NO984446L (no) FremgangsmÕte for behandling av smerte
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
NO982582L (no) Fremgangsmaate for behandling av smerte
HUP0202836A2 (hu) Piridazinonszármazék új alkalmazása
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application